# EIK1005

Source: https://onco.cc/drugs/eik1005/  
OnCo record `eik1005` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

EIK1005 is a small-molecule inhibitor from Eikon Therapeutics, in registered phase 2 trials for colorectal cancer, endometrial cancer.

## Summary

EIK1005 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Eikon Therapeutics, in colorectal cancer, endometrial cancer. Described in the registry record as a eik1005 is a selective inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: EIK1005
- Modality: Small-molecule inhibitor
- Mechanism: Described in the registry record as a eik1005 is a selective inhibitor; the trial entries below carry the sponsor's wording.

## Sources

- ClinicalTrials.gov: trials of EIK1005: https://clinicaltrials.gov/search?intr=EIK1005

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- companies: [Eikon Therapeutics](https://onco.cc/companies/eikon-therapeutics/)
- trials: [EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Partic](https://onco.cc/trials/nct07262619/)

---
JSON: https://onco.cc/api/v1/entities/eik1005.json